Analytical estimation methods for determination of sorafenib

Thangabalan Boovizhikannan *, Jagadish Kuruba, Mahasweta Goswami and Bhavya Maddineni

Department of Pharmaceutical Analysis, Sri Venkateswara College of Pharmacy, RVS Nagar, Tirupati Rd, Chittoor, Andhra Pradesh 517127, India.
 
Review
World Journal of Biology Pharmacy and Health Sciences, 2022, 12(02), 016–026.
Article DOI: 10.30574/wjbphs.2022.12.2.0184
Publication history: 
Received on 27 September 2022; revised on 04 Noveber 2022; accepted on 07 November 2022
 
Abstract: 
Sorafenib is an anticancer drug is used to treat late stage kidney and liver cancer. Sorafenib is used to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the kidneys). Sorafenib is also used to treat hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery and a certain type of thyroid cancer that has spread to other parts of the body and cannot be treated with radioactive iodine. Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. There are many reported analytical methods for estimation of Sorafenib. The present work list outs the various analytical methods for the estimation of the drug. 
 
Keywords: 
Sorafenib; Antineoplastic agent; Estimation methods; Review
 
Full text article in PDF: